Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses.
Diabetes, obesity & metabolism（2023）
摘要
STEP 1 NCT03548935, STEP 4 NCT03548987.
更多查看译文
关键词
GLP-1 analogue,cardiovascular disease,obesity therapy,randomized trial,weight control
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要